UV Flu Technologies Signs a Distribution Agreement with DPG Distribution
CENTERVILLE, Mass., Dec. 4, 2012 /PRNewswire/ -- UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") is pleased to announce that it has signed a distribution agreement with the Davison Product Group, LLC, aka DPG Distribution, of Heathrow, Florida.
DPG is one of the country's largest distributors of high-end retail consumer electronic products, with a client list of hundreds of the nation's foremost retail chains. DPG sales channels also include state and federal government, military, and online merchants.
"We are thrilled to be working with DPG," said Jack Lennon, President of UV Flu. "DPG is one of the nation's premier retail distributors, offering worldwide service in sales, marketing, distribution and in-store support. We particularly feel akin to their focus in providing the ultimate customer experience through products of impeccable quality, and the latest technology and innovation. DPG clients include catalogue retailers Frontgate and Brookstone and leading retail clients Costco, Amazon, Best Buy, QVC and countless others. In addition to the retail contacts, DPG offers PO funding for its manufacturing partners through Wells Fargo Bank, which will help us ramp up our production capacity in the next quarter," said Mr. Lennon.
Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com, and click on the 5 minute video describing the Viratech UV-400.
About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer; manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector ($7 billion in 2011). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Toll-Free: 1-877-358-5545 (FLU-KILL)
SOURCE UV Flu Technologies, Inc.